Cardiometabolic and Inflammation Markers Investigations may track blood pressure, heart rate, inflammatory cytokines, and surrogate cardiovascular risk markers in response to longacting incretin modulation
The trial aims to enroll 700 participants, and will run 78 weeks (estimated readout 1H 2025)
Are they destined to change the future of pharma
Persistent diarrhea or constipation lasting more than a few days should be reported
stopping GLP-1 injectables Most people don't realize that synthetic GLP-1 hormones reduce your natural GLP-1 production to zero -- a normal response when you're getting hormones exogenously (your body goes "on holiday" and stops producing)
By month 4, GI side effects fade into background noise for 85%+ of patients, leaving appetite suppression as the primary ongoing effect, which is the desired therapeutic response